Fujifilm Corporation

Mikinaga Mori

Takeshi Matsumoto

Makoto Ono

Kohei Ono

Takahiro Sekiguchi

Takayuki Kato

Takayoshi Oyamada

Naoki Yamada

Noriyuki Kasagi

Tsukasa Kitahashi

Takayuki Kobayashi

Kentaro Numajiri

Susumu Shimoyama

Hideyuki Karaki

Jun Arakawa

Junichi Katada

Shinji Mima

Taisuke Endo

Hiroyuki Chiku

Masayasu Konishi

Atsuhiko Wada

Ken Okada

Hiroyuki Kitaoka

Hiroki Terada

Tadaaki Ioroi

Yuta Yoshino

Hayato Ogura

Ritsuko Hori

Tamami Higuchi

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition in which liposomes encapsulate a drug with an immune checkpoint inhibitor. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin, and cholesterols, the liposome composition includes a drug and has art inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.

Combined pharmaceutical formulation comprising drug-containing liposome composition and immune checkpoint inhibitor

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.

Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation

An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.

Liposome composition and method for producing the same

Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.

Liposome composition and method for producing same

An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.

Liposome composition and pharmaceutical composition

An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Tumor therapeutic agent and kit containing gemcitabine liposome composition

An object of the present invention is to provide a lipid particle composition containing panobinostat or a salt thereof and exhibiting a high bone marrow-targeting capability, and a pharmaceutical composition including the lipid particle composition. According to the present invention, provided is a lipid particle composition containing panobinostat or a salt thereof, in which a lipid particle contains a phospholipid and cholesterol.

Lipid particle composition and pharmaceutical composition

Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.

A device for assay can evenly develop solution, and performs highly accurate and sensitive measurement. A first device part () maintains a second insoluble carrier () and a third insoluble carrier () in such a manner that they overlap with each other at a detection portion () of a first insoluble carrier (). These three carriers (), () and () are housed not in contact with each other. A pressing unit () having a pressing surface () that is parallel to the detection portion () is provided on an inner surface of the second device part () facing the detection portion (). The pressing surface () is displaced by being pressed toward the detection portion (), and presses, from the upper side of the first insoluble carrier (), the second insoluble carrier () and the third insoluble carrier () onto the first insoluble carrier (). The first device part () and the second device part () are joined together.

Method and device for assay

A plurality of kinds of liquids, which are of at least three kinds, containing (a) a test body solution containing at least one kind of an analyte, and (b) at least two kinds of liquids selected from the group consisting of a reagent solution, an amplifying solution, and a detecting solution, are fed to a detection site containing a specific binding substance with respect to the analyte. A qualitative analysis or a quantitative analysis of the analyte contained in the test body solution is thereby performed. Directions of liquid feeding of all of the plurality of the kinds of the liquids vary from one another, and the plurality of the kinds of the liquids are caused to intersect with one another at the detection site.

Assay method

Cartridge for immunochromatographic test device

Growing community of inventors

Ashigarakami-gun, Japan

Mikinaga Mori